Elafibranor Granted Priority Review for Primary Biliary Cholangitis
The FDA has accepted for Priority Review the NDA for elafibranor for the second-line treatment of primary biliary cholangitis.
Source: empr.com
Itch Numeric Rating Scale News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Itch Numeric Rating Scale. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Itch Numeric Rating Scale Today - Breaking & Trending Today
Nektar Therapeutics Reports Third Quarter 2023 Financial Results
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2023. Cash and investments in...
Source: prnewswire.com
Recombinant IL-2 Shows Potential in Atopic Dermatitis
"This is the first study to demonstrate the therapeutic potential of rezpegaldesleukin," said Jonathan Silverberg, MD, PhD, MPH, who presented results of a phase 1b study.
Source: medscape.com
Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
Seven abstracts to be presented demonstrating treatment effects of Bylvay® in two cholestatic liver diseases, progressive familial intrahepatic cholestasis and Alagille syndrome Data to be... | June 12, 2023
Source: marketscreener.com
Baricitinib 'potential therapeutic option' for moderate to severe atopic dermatitis
A 4 mg dose of baricitinib was associated with significant improvement over placebo in a number of efficacy parameters in patients with moderate to severe atopic dermatitis, according to a study. “Baricitinib, an oral selective Janus kinase (JAK)1/JAK2 inhibitor, is approved in many countries for moderate-to-severe atopic dermatitis (AD) in adult patients who are candidates
Source: healio.com